Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 11/20 | 0.52 |
| ▸ | GABRB3 | P28472 | 11/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 11/20 | 0.52 |
| ▸ | GABRA3 | P34903 | 11/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 8/20 | 0.52 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | HTR5A | P47898 | 3/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1923848 | 0.86 | GABRG2 (0.40) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL1066139 | 0.79 | GABRG2 (0.52) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL23607649 | 0.77 | GABRG2 (0.38) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL1079862 | 0.76 | GABRG2 (0.58) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL30549074 | 0.75 | GABRG2 (0.51) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL23536381 | 0.75 | GABRG2 (0.51) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2651744 | 0.75 | GABRG2 (0.51) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2653518 | 0.75 | KDM1A (0.44) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2649908 | 0.75 | GABRG2 (0.49) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2652557 | 0.74 | MAP4K4 (0.49) | GABRG2GABRB3GABRA5GABRA3GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279580-B2 | Imidazo-pyridine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LIMITED (GB) | 2007-10-09 | — | — | US | disclosed |
| EP-1511747-B1 | IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2006-04-12 | — | — | EP | disclosed |
| EP-1343788-B1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2005-11-23 | — | — | EP | disclosed |
| US-6960598-B2 | (1,8) naphthyridines as gaba ligands, their pharmaceutical compositions and uses | MERCK SHARP & DOHME LTD. | 2005-11-01 | — | — | US | disclosed |
| US-6936608-B2 | Imidazo-triazine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LTD. | 2005-08-30 | — | — | US | disclosed |
| US-20050165048-A1 | Imidazo-pyridine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2005-07-28 | — | — | US | disclosed |
| EP-1381606-B1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2005-07-20 | — | — | EP | disclosed |
| US-6900215-B2 | For therapy of disorders of central nervous system, including anxiety, convulsions and cognitive disorders | MERCK SHARP & DOHME LTD. (GB) | 2005-05-31 | — | — | US | disclosed |
| EP-1511747-A1 | IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2005-03-09 | — | — | EP | disclosed |
| US-20040171633-A1 | (1, 8) naphthyridines as gaba ligands, their pharmaceutical compositions and uses | MERCK SHARP & DOHME LTD. (GB) | 2004-09-02 | — | — | US | disclosed |
| US-20040023964-A1 | Imidazo-triazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2004-02-05 | — | — | US | disclosed |
| EP-1381606-A1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2004-01-21 | — | — | EP | disclosed |
| WO-2003099816-A1 | IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2003-12-04 | — | — | WO | disclosed |
| EP-1343788-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2003-09-17 | — | — | EP | disclosed |
| WO-2003006464-A1 | (1,8) NAPHTHYRIDINES AS GABA LIGANDS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES | MERCK SHARP & DOHME LIMITED (GB) | 2003-01-23 | — | — | WO | disclosed |
| US-20020193385-A1 | Imidazo-pyrimidine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2002-12-19 | — | — | US | disclosed |
| WO-2002074773-A1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002038568-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193385-A1 | Imidazo-pyrimidine derivatives as ligands for gaba receptors | GABRA3, GABRA1, GABRA2 | GABRG2 15/4885GABRB3 8/4885GABRA5 5/4885 |
| US-20050165048-A1 | Imidazo-pyridine derivatives as ligands for gaba receptors | GABRA3, GABRA2, GABRA5 | GABRG2 15/4885GABRB3 6/4885GABRA5 3/4885 |
| US-20040023964-A1 | Imidazo-triazine derivatives as ligands for gaba receptors | GABRA2, GABRA5, GABRA1 | GABRG2 14/4885GABRB3 9/4885GABRA5 2/4885 |
| US-20040171633-A1 | (1, 8) naphthyridines as gaba ligands, their pharmaceutical compositions and uses | GABRA1, GABRA4, GABRA6 | GABRG2 14/4885GABRB3 11/4885GABRA5 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.